{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"77.4","value":"33.3"},{"groupId":"OG001","lowerLimit":"65.4","upperLimit":"91.9","value":"82.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"PFS will be estimated using Kaplan Meier method, as well as, their corresponding 95% confidence intervals.\n\nProgressive disease requires at least 1 of the following Perpendicular diameters: An individual node/lesion must be abnormal with: longest diameter 1.5 cm and Increase by 50% from perpendicular diameters nadir and an increase in longest diameter or shortest diameter from nadir 0.5 cm for lesions 2 cm 1.0 cm for lesions 2 cm. In the setting of splenomegaly, the splenic length must increase by 50% of the extent of its prior increase beyond baseline (e.g., a 15-cm spleen must increase to 16 cm). If no prior splenomegaly, must increase by at least 2 cm from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Each participant in the dose-finding cohort must have completed at least cycle 1 (or 21 days) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). Starting dose of ibrutinib is 560 mg PO.","id":"OG000","title":"Dose-finding Cohort"},{"description":"Each participant in the dose expansion cohort may receive treatment for a maximum of 6 cycles (21-day cycle length) of ibrutinib plus rituximab (R)-dose adjusted (da)-etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin (EPOCH). MTD of ibrutinib is 560 mg PO.","id":"OG001","title":"Dose Expansion Cohort"}],"paramType":"NUMBER","populationDescription":"Participants received study treatment (ibrutinib plus R-da-EPOCH)","reportingStatus":"POSTED","timeFrame":"2 years","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}